Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Bet on super six stocks for March 6

      On CNBC-TV18's show Super Six, market gurus Vishal Kshatriya, Edelweiss, Shardul Kulkarni, Angel Broking and Rakesh Gandhi, FRR shares, place their bets on two stocks each, thus offering investors a variety of options to choose from. Investors can read into the detailed analysis before agreeing to any or all the bets.

    • 6 trading bets that can fetch you handsome returns

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, manasjaiswal.com, Rajeev Agarwal, dynamixresearch.in and Vikrant Jadeja, vibranttrades.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Ranbaxy Laboratories on dips: Sukhani

      Buy Ranbaxy Laboratories on dips, says Sudarshan Sukhani of s2analytics.com. The chart suggests that the stock is deeply oversold. If not anything, will get a relief rally, if there is something more the positional traders will benefit.

    • Ranbaxy Labs can move to Rs 450, says SP Tulsian

      Ranbaxy Labs can move to Rs 450, says SP Tulsian of sptulsian.com.

    • Hold Ranbaxy for two to three years: Tulsian

      SP Tulsian of sptulsian.com advised holding Ranbaxy Labs for two to three years. He feels the stock will see good appreciation.

    • Buy Ranbaxy Laboratories: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ranbaxy Laboratories with stoploss of Rs 400.

    • Sell Ranbaxy Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can sell Ranbaxy Laboratories. At Rs 405 this stock has broken down from a strong support level and that is worrying because there is nothing to hold it now.

    • KYI: How you should trade stocks next week

      It was a volatile day on the Dalal Street as the markets turned around in late trade. Indices closed flat after a weak start. The Nifty closed just shy of 5,900 and the Sensex ended at 19,468.

    • Super Six stocks you can bet on Jan 14

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Vikrant Jadeja of Vibrant Trades and Rajeev Agarwal of www.dynamixresearch.in, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Prefer Ranbaxy Labs to Dr Reddys Labs: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can prefer Ranbaxy Laboratories to Dr Reddys Laboratories.

    • See upside in Ranbaxy Laboratories: Sukhani

      See upside in Ranbaxy Laboratories, says Sudarshan Sukhani of s2analytics.com.

    • Super six stocks ideas for December 20

      On CNBC-TV18's show Super Six, market gurus Vikrant Jadeja of Vibranttrades.com, Shardul Kulkarni of Angel Broking and Rajesh Jain of Religare Sec, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Arvind, Ranbaxy: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Arvind. “Ranbaxy is a worth buying into because the risk is small, “he adds.

    • Buy SBI, Ranbaxy Labs: Nirmal Bang

      Dipesh Mehta, Nirmal Bang Securities is bullish on SBI, Ranbaxy Laboratories and has recommended buy rating on the stocks.

    • Ranbaxy Laboratories can test Rs 600: Jai Bala

      Ranbaxy Laboratories can test Rs 600, says Jai Bala, cashthechaos.com.

    • Ranbaxy Labs has good support around Rs 485- 490: Mohindar

      Ranbaxy Labs has good support around Rs 485- 490, says Rahul Mohindar of viratechindia.com.

    • Stock picks: 9 trading tips, 2 multibagger ideas

      The Indian market has been rangebound over the last many days. It is entering an important week today. The November futures and options contracts will expire on this Thursday. The derivative expiry week is usually very volatile. Moneycontrol brings to you some of the recommendations given by experts.

    • Sell Ranbaxy Labs, says Sukhani

      Sudarshan Sukhani, s2analytics.com advice traders to sell Ranbaxy Labs.

    • Buy Manappuram Finance; Avoid Ranbaxy: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that one can buy Manappuram Finance with a target of Rs 40. However, one should one should avoid Ranbaxy Laboratories; it is not a buy on dips stock.

    • New drug pricing policy: Which cos will be impacted most?

      Chirag Talati, Espirito Santo Securities says the policy had been anticipated for long. According to him, Cipla, Cadila and Ranbaxy will be impacted negatively.

    • Pharma pricing policy to hurt Cipla, Ranbaxy, Lupin: Vijay

      PN Vijay, Portfolio Manager, askpnvijay.com, says that companies like Cipla and Ranbaxy would be largely affected by the pricing policy because they have large presence in domestic life saving drugs space and to some extent affect will be seen on Lupin.

    • 6 stocks that should do well today

      On CNBC-TV18's show Super Six, market gurus Shardul Kulkarni of Angel Broking, Vikrant Jadeja of Vibrant Trades and Rajeev Agarwal of www.dynamixresearch.in, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Tulsian recommends Radico Khaitan, KFA, HDIL

      In an interview to CNBC-TV18, SP Tulsian of sptulsian.com tells he is positive on most Mumbai-based realty stocks. He says he has a positive stance on HDIL, DB Realty, Ajmera, Orbit Corporation.

    • Buy Ranbaxy Labs, target of Rs 620-630: Vivek Kumar

      Vivek Kumar, SBI Cap Securities advice traders to buy Ranbaxy Labs for target of Rs 620-630.

    • Buying opportunity seen in Ranbaxy Labs, says Sukhani

      Buying opportunity is seen in Ranbaxy Labs and one can book profit in Jubilant Foodworks, says Sudarshan Sukhani of s2analytics.com.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347